Potent galloyl-based selective modulators targeting multidrug resistance associated protein 1 and P-glycoprotein

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Multidrug resistance (MDR) is a major cause of chemotherapy failure in cancer treatment.
• Increased expression of ATP binding cassette (ABC) transporters, such as P-glycoprotein (P-gp) and MRP1, is a primary mechanism of MDR.
• Inhibiting these transporters is crucial for overcoming drug resistance.

Purpose of the Study:

• To design and synthesize novel galloyl benzamide derivatives.
• To evaluate the selectivity and potency of these derivatives as inhibitors of MRP1 and P-gp.
• To explore structure-activity relationships for developing effective MDR circumvention strategies.

Main Methods:

• Synthesis of a library of galloyl benzamide derivatives.
• In vitro assays to assess the inhibitory activity against MRP1 and P-gp.
• Structure-activity relationship analysis to identify key structural features for selectivity.

Main Results:

• Certain gallamides and pyrogallol-1-monomethyl ethers demonstrated high affinity and selectivity for MRP1 inhibition.
• Trimethyl ether galloyl anilides showed moderate to very high and selective inhibition of P-gp.
• The galloyl benzamide scaffold allows for tailored decoration to achieve specific inhibition of target ABC transporters.

Conclusions:

• Novel galloyl benzamide derivatives can be effectively designed to selectively inhibit MRP1 or P-gp.
• These selective inhibitors represent promising candidates for combination therapy to overcome chemotherapy resistance.
• Targeted inhibition of ABC transporters offers a viable strategy to improve cancer treatment outcomes.